GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Cash Flow for Dividends

Akero Therapeutics (STU:0K4) Cash Flow for Dividends : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Cash Flow for Dividends?

Akero Therapeutics's cash flow for dividends for the three months ended in Dec. 2024 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Akero Therapeutics Cash Flow for Dividends Historical Data

The historical data trend for Akero Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics Cash Flow for Dividends Chart

Akero Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial - - - - -

Akero Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akero Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akero Therapeutics Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Cash Flow for Dividends
Comparable Companies
RYTM RARE SLNO SWTX CRNX CRSP IMVT SRRK MRUS ACLX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AKRO:USA
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Website
https://www.akerotx.com
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines